Longevity Tech Stuns CES

Person interacting with a smartwatch displaying health data

New wearables and AI tools at CES 2026 promise to extend your healthy years to 100, turning aging into a data-driven triumph over decline.

Story Highlights

CES 2026 featured nearly 100 longevity exhibitors showcasing consumer tech for proactive aging.
Wearables like Ultrahuman Ring AIR track sleep and biometrics for personalized insights.
Drugs like Ozempic cut mortality by 50%, proving repurposed meds extend healthspan.
AI companions and exoskeletons empower independence, shifting from reactive to preventive care.
Experts predict healthspan to 100+ via ambient data and cellular therapies.

CES 2026 Unveils Wearables Revolutionizing Daily Health Monitoring

CES 2026 in early 2026 drew nearly 100 longevity exhibitors. Ultrahuman Ring AIR tracks sleep, heart rate variability, and recovery metrics continuously. Ascentiz exoskeletons support mobility for seniors, reducing fall risks. Smart scales measure cardiac blood flow beyond weight, alerting users to heart issues early. These devices collect ambient data, enabling AI to predict health declines before symptoms appear. Rene Quashie, CTA VP of Digital Health, spotlighted this shift to consumer-accessible tech.

AI Companions and Predictive Tools Personalize Longevity Care

ElliQ serves as an AI companion for older adults, combating isolation with conversations and reminders. Cleerly AI detects heart plaque via scans, preventing silent killers like atherosclerosis. Noom’s at-home biomarker device tracks GLP-1 drug effects like Ozempic, which reduced hospitalizations and deaths by 50% per JAMA studies cited by Nir Barzilai. Dr. Luu of Noom champions “ambient longevity,” where lifestyle data fuels personalized AI assistants. This democratizes elite biohacking through apps.

Drugs and Biotech Push Healthspan Boundaries with Proven Results

Ozempic and Mounjaro, GLP-1 agonists approved since 2017, now show longevity benefits by slashing mortality. Barzilai, from Albert Einstein College, argues these drugs slow aging processes, eyeing a 120-year lifespan cap. Historical precedents include metformin trials like TAME since the 2010s. Post-COVID remote monitoring accelerated wearables from Fitbit eras into AI precision medicine. Gene therapies using Yamanaka factors advance from preclinical to clinical stages.

Hyperbaric oxygen therapy trials pre-2026 improved cognition. Multi-omics tests now gauge biological age in clinics, guiding interventions.

How New Longevity Tech Could Help You Reach 100 https://t.co/5F5thLe7f0 pic.twitter.com/69Z2xH7SIE

— Healthy Hoss 🍎 (@HealthyHoss) February 25, 2026

Stakeholders Drive Longevity Economy Amid Access Challenges

Companies like Ultrahuman, Cleerly, and Noom target market growth in the booming longevity sector. Venture-backed Retro Biosciences and Neuralink, funded by Sam Altman and Elon Musk, launch trials in early 2026. Big Pharma partners with AI startups, blending profits with healthspan goals. Physicians like Dr. Luu and Barzilai endorse data-driven adoption. Common sense favors these tools for self-reliant aging, aligning with conservative values of personal responsibility over endless government healthcare dependence. Yet early access favors the affluent.

Impacts Reshape Health, Economy, and Society

Short-term gains include fewer doctor visits via telehealth and wearables, plus GLP-1 hospitalization drops. Long-term, cellular rejuvenation extends healthspan past 100. Older adults gain independence; chronic patients manage diabetes and hearts better. The longevity economy surges with AI and regenerative markets. Socially, healthspan prioritizes mental fitness amid centenarian rises. Policy may fund trials as demographics age, though skeptics warn of hype in unproven trials and equity gaps.